Advertisement

Topics

Seattle Genetics Suspends Trial Of Leukemia Treatment After Data Showed Higher Rate Of Death

11:22 EDT 19 Jun 2017 | Topix

Seattle Genetics Inc. said Monday that it is discontinuing the Phase 3 clinical trial of its acute myeloid leukemia treatment, SGN-CD33A, after data indicated a higher rate of deaths, including fatal infections. The company said it will suspend patient enrollment and treatment, and will closely review the data and consult with the Food and Drug Administration to determine future plans.

Original Article: Seattle Genetics Suspends Trial Of Leukemia Treatment After Data Showed Higher Rate Of Death

NEXT ARTICLE

More From BioPortfolio on "Seattle Genetics Suspends Trial Of Leukemia Treatment After Data Showed Higher Rate Of Death"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...